Xeris Biopharma Holdings XERS Cash Flow Statement (2020-2026)

NASDAQ XERS
$16.52 +0.69 (+4.36%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Xeris Biopharma Holdings Quarterly Cash Flow Statement

Periods 25 quarters
Latest Sep 2026

Xeris Biopharma Holdings reported cash from operations of $35.47M and free cash flow of $35.63M for the quarter ended Sep 2026, up 92.4% year over year. This cash flow statement covers 25 quarters of results from Sep 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-50.79M-33.71M-26.19M-21.83M-12.93M-16.83M-19.84M-12.19M-13.39M-18.98M-15.01M-15.74M-5.11M-9.22M-1.93M0.62M11.08M2.23M-31.10M11.29M
Depreciation, Depletion & Amortization
Amortization of IntangiblesAmort. of Intangibles
0.55M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M2.71M
Amortization of Deferred ChargesAmort. Deferred Charges
0.27M0.22M0.50M0.40M0.49M0.55M0.60M0.60M0.51M0.60M0.80M0.80M0.81M0.84M0.80M0.80M0.89M0.90M0.90M0.90M
Depreciation & Amortization (CF)Dep. & Amort.
0.35M0.32M0.35M0.36M0.37M0.36M0.39M0.39M0.35M0.33M0.28M0.31M0.31M0.32M0.33M0.30M0.31M0.34M0.32M0.30M
Share-based CompensationStock Comp.
2.74M3.30M3.15M2.94M2.77M2.56M2.93M2.46M2.77M3.77M4.23M6.77M3.60M4.44M5.01M7.64M5.27M4.14M11.07M10.80M
Deferred Taxes
-0.68M0.68M-1.25M0.31M0.75M-3.32M
Other non-cash itemsOther Non-Cash
1.32M-0.10M0.43M0.11M0.78M2.84M0.20M0.18M0.60M0.11M0.12M0.15M0.16M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.45M5.93M2.37M1.76M3.31M0.03M-0.64M15.74M-6.77M-1.78M5.03M-1.30M-0.72M5.92M6.72M0.70M-2.70M5.25M1.81M10.49M
Change in InventoryChange Inventory
2.27M0.16M0.15M1.66M5.51M3.82M7.43M2.15M1.40M2.33M2.27M1.05M3.14M3.62M7.57M4.09M4.01M-0.85M9.50M-2.70M
Change in Account PayablesChange Payables
4.35M2.17M-4.46M-2.72M0.69M6.94M0.08M0.30M-0.35M-4.47M-1.59M1.65M-5.20M4.06M-4.43M2.00M-1.70M4.25M0.29M-1.17M
Change in Accrued ExpensesChange Accrued Exp.
7.91M-13.66M1.18M0.34M0.75M-13.93M2.73M-0.80M6.15M-1.12M1.57M-1.05M4.25M-8.58M5.35M2.83M3.70M-1.50M-1.51M7.39M
Change in Other Operating AssetsOther Assets Change
-3.68M0.06M0.86M1.84M1.13M1.23M-2.05M-0.34M-2.04M1.86M-0.28M-0.22M0.31M-1.53M-0.27M5.15M-1.25M-0.15M4.49M-1.33M
Change in Other Operating LiabilitiesOther Liabilities Change
3.00M-1.30M1.24M5.13M5.50M2.05M5.96M6.97M1.29M2.37M3.65M-0.40M-1.68M2.66M6.14M11.82M-2.08M1.14M10.55M10.43M
Other Working Capital ChangesOther WC Changes
6.68M-1.36M0.38M3.29M4.37M0.82M8.01M7.32M3.32M0.51M3.93M-0.19M-1.99M4.19M6.41M6.66M-0.82M1.28M6.06M11.76M
Cash from OperationsCash from Ops.
-28.95M-48.41M-20.61M-17.75M-16.12M-26.14M-13.74M-14.61M7.47M-20.30M-10.35M-8.31M1.98M-10.03M0.18M18.43M20.04M9.87M8.26M35.47M
Investing Activities
Capital ExpendituresCapex
0.13M0.02M-0.23M-0.18M-0.13M-0.24M-1.55M-0.35M-0.13M-0.16M-0.40M-0.09M-0.22M-0.01M-0.28M-0.07M-0.33M-0.33M-0.21M-0.16M
Change in Property, Plant and EquipmentChange in PP&E
-0.13M-0.02M0.23M0.18M0.13M0.24M1.55M0.35M0.13M0.16M0.40M0.09M0.22M0.01M0.28M0.07M0.33M0.33M0.21M0.16M
Purchase of InvestmentsInvestments Purchased
12.24M43.74M24.49M5.00M5.00M
Sale and Maturity of InvestmentsInvestments Sold
10.50M6.70M12.10M6.89M9.30M10.00M15.00M15.00M5.00M10.00M15.00M10.24M
Cash from Investing ActivitiesCash from Investing
36.60M6.72M11.87M6.71M9.17M-43.98M8.45M14.66M14.87M-19.65M4.60M9.91M10.02M-0.01M-0.28M-0.07M-0.33M-0.33M-0.21M-0.16M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
97.30M48.92M50.00M
Long-Term Debt RepaymentsLT Debt Repayment
43.50M
Net Long-Term Debt Issued (Repaid)Net LT Debt
53.80M48.92M50.00M
Net Debt Issuances and RepaymentsNet Debt Issuance
53.80M48.92M50.00M
Change in Capital Stock
Common Stock IssuedStock Issued
0.29M30.01M0.51M0.32M0.58M0.46M0.71M0.56M4.86M1.80M14.33M1.27M8.18M2.13M0.68M
Net Shares Issued and RepurchasedNet Shares Issued
0.29M30.01M0.51M0.32M0.58M0.46M0.71M0.56M4.86M1.80M14.33M1.27M8.18M2.13M0.68M
Net Equity Issued and RepurchasedNet Equity Issued
0.29M30.01M0.51M0.32M0.58M0.46M0.71M0.56M4.86M1.80M14.33M1.27M8.18M2.13M0.68M
Other financing activities (as filed)
-0.17M-5.61M-0.20M-0.19M-0.08M-0.86M-0.03M-0.07M-1.23M-3.43M-0.05M-0.08M-0.17M-8.00M-0.86M-0.48M-1.54M-17.02M-0.19M-0.75M
Cash from Financing ActivitiesCash from Financing
0.13M78.19M0.31M-0.19M49.16M-0.86M0.56M-0.07M-1.23M35.19M0.66M-0.08M0.40M-3.14M0.94M13.85M-0.27M-8.84M1.94M-25.98M
Additional items
Exchange Rate EffectFX Effect
0.00M0.00M0.00M
Change in Cash
7.78M36.50M-8.43M-11.23M42.21M-70.98M-4.74M-0.03M21.11M-4.76M-5.09M1.53M12.39M-13.18M0.85M32.21M19.44M0.71M10.00M9.34M
Ending Cash Balance
67.27M103.77M95.34M84.11M126.31M55.33M50.60M50.57M71.67M66.92M61.83M63.36M75.74M62.56M63.41M95.62M115.06M115.77M125.77M135.10M
Free Cash FlowFCF
-29.08M-48.43M-20.38M-17.58M-15.99M-25.90M-12.20M-14.27M7.60M-20.14M-9.95M-8.22M2.20M-10.02M0.46M18.50M20.38M10.20M8.47M35.63M
Net Cash FlowNCF
7.78M36.50M-8.43M-11.23M42.21M-70.98M-4.74M-0.03M21.11M-4.76M-5.09M1.53M12.39M-13.18M0.85M32.21M19.44M0.71M10.00M9.34M
Interest Paid
1.94M3.77M1.00M2.92M3.17M9.83M5.38M6.86M5.62M1.50M6.82M12.61M6.02M13.09M7.08M6.95M5.35M5.38M6.78M

Xeris Biopharma Holdings Cash Flow Statement API

Pull Xeris Biopharma Holdings's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=XERS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY